- Report
- July 2024
- 157 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- January 2025
- 180 Pages
Global
From €5656EUR$5,950USD£4,752GBP
Point-of-Care (POC) HIV Testing is an aspect of infectious disease diagnostics focusing on providing rapid and accessible testing for Human Immunodeficiency Virus (HIV). POC tests are designed to deliver results quickly, often within minutes, facilitating immediate counseling and linkage to care. These tests are vital in various settings, including clinics, community-based programs, and areas where traditional lab-based testing may not be readily available or practical.
In the broader context of infectious disease testing, POC HIV Testing stands out as a crucial preventative and diagnostic tool. It enables healthcare providers to screen patients for HIV in a single visit, which is essential for early detection and management of the disease. POC testing for HIV often requires minimal training and can be performe.d outside of conventional laboratory settings. Rapid diagnosis has not only improved patient outcomes by starting treatment sooner but has also helped in reducing transmission rates.
Among the companies active in the POC HIV Testing market are Abbott Laboratories, which provides the Determine HIV-1/2 Ag/Ab combo test; OraSure Technologies, known for its OraQuick advance rapid HIV-1/2 antibody test; Bio-Rad Laboratories with its Bio-Rad Geenius HIV 1/2 Supplemental Assay; and Roche Diagnostics, offering the Cobas HIV-1 test for use on the Cobas platform. These players are part of the vibrant landscape of diagnostic companies advancing POC technologies for infectious diseases like HIV. Show Less Read more